CpG oligonucleotide (ODN), a kind of Toll-like receptor 9 (TLR9) agonist, proves to be a safe and promising adjuvant for the development of new-generation vaccines and has been used in an approved recombinant hepatitis B vaccine (HEPLISAV-B®) [13]. Here, TLR9 is linked to hepatitis B virus infection.